Study design
BLIND
This study was implemented as part of a series of case-control experiments to test the hypothesis that there is a difference in GABA pathway function in people with and without ASD [Medical cover was provided and participants were asked to remain at our unit at least four hours after drug/placebo intake. The medic was ‘blind’ to the order of administration but had access to the visit placebo/drug allocation information if needed (it was not). If a participant had experienced side effects that were more than moderate in the opinion of the study clinician and after discussion with the Chief Investigator, unblinding occurred to try to avoid exposure to a higher dose of arbaclofen on a subsequent visit.